Is ELIXF or JNJ a better dividend investment in 2026?

ELIXF currently yields 5970.15% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: ELIXF offers higher current income.

What is the dividend yield difference between ELIXF and JNJ?

ELIXF has a forward dividend yield of 5970.15% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 5968.02 percentage points.

Home › Compare › ELIXF vs JNJ

ELIXF vs JNJ: Dividend Comparison 2026

ELIXF yields 5970.15% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ELIXF wins by $349757300762302.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ELIXF

● Live price

5970.15%

Share price

$0.03

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$349757300762302.00M

Annual income

$338,600,487,421,434,700,000.00

Full ELIXF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — ELIXF vs JNJ

📍 ELIXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ELIXF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ELIXF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ELIXF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELIXF

Annual income on $10K today (after 15% tax)

$507,462.69/yr

After 10yr DRIP, annual income (after tax)

$287,810,414,308,219,520,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, ELIXF beats the other by $287,810,414,308,219,520,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELIXF + JNJ for your $10,000?

ELIXF: 50%JNJ: 50%

100% JNJ50/50100% ELIXF

Portfolio after 10yr

$174878650381151.00M

Annual income

$169,300,243,710,717,360,000.00/yr

Blended yield

96.81%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ELIXF

No analyst data

Altman Z

-68.9

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELIXF buys

JNJ buys

No recent congressional trades found for ELIXF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricELIXFJNJ

Forward yield	5970.15% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$349757300762302.00M ✓	$30.3K
Annual income after 10y	$338,600,487,421,434,700,000.00 ✓	$4,689.40
Total dividends collected	$349006491373237.88M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ELIXF vs JNJ ($10,000, DRIP)

Year	ELIXF Portfolio	ELIXF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$607,715	$597,014.93	$10,592	$272.30	+$597.1K → ELIXF
2	$34,558,188	$33,907,932.79	$11,289	$357.73	+$34.55M → ELIXF
3	$1,839,034,548	$1,802,057,287.52	$12,123	$472.89	+$1839.02M → ELIXF
4	$91,591,647,409	$89,623,880,441.98	$13,141	$629.86	+$91591.63M → ELIXF
5	$4,269,634,661,039	$4,171,631,598,311.20	$14,408	$846.81	+$4269634.65M → ELIXF
6	$186,311,225,789,697	$181,742,716,702,385.70	$16,021	$1,151.60	+$186311225.77M → ELIXF
7	$7,611,116,385,606,142	$7,411,763,374,011,165.00	$18,122	$1,588.22	+$7611116385.59M → ELIXF
8	$291,118,268,537,960,000	$282,974,374,005,361,470.00	$20,930	$2,228.20	+$291118268537.94M → ELIXF
9	$10,426,928,355,950,688,000	$10,115,431,808,615,070,000.00	$24,792	$3,191.91	+$10426928355950.66M → ELIXF
10	$349,757,300,762,302,000,000	$338,600,487,421,434,700,000.00	$30,274	$4,689.40	+$349757300762302.00M → ELIXF

ELIXF vs JNJ: Complete Analysis 2026

ELIXF — Stock

Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cannabis-related businesses, which are fully licensed for cultivation, production, and/or sale of medical and specialty cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada.

Full ELIXF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this ELIXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELIXF vs SCHD ELIXF vs JEPI ELIXF vs O ELIXF vs KO ELIXF vs MAIN ELIXF vs ABBV ELIXF vs MRK ELIXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.